SCHEMBL866323

SCHEMBL866323

O=C(O)Cc1coc(-c2cc(C(F)(F)F)ccc2Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF4E P06730 3/20 0.43
AGPAT2 O15120 2/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
ALDH1A1 P00352 2/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
IL2 P60568 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
MRGPRX4 Q96LA9 2/20 0.38
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13149031 0.85 EIF4E (0.37) EIF4EAGPAT2JAK2PPARGPPARA
SCHEMBL10029592 0.81 AGPAT2 (0.42) EIF4EAGPAT2ALDH1A1SMN1; SMN2
SCHEMBL28620228 0.78 NR4A2 (0.48) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL628795 0.77 RXRA (0.49) PPARGPPARAKMT2A
SCHEMBL629227 0.77 EIF4E (0.53) EIF4EALDH1A1HTTSMN1; SMN2
SCHEMBL628790 0.76 NOTUM (0.49) EIF4EKMT2ACTSSCTSK
SCHEMBL629167 0.72 RXRA (0.53) PPARGPPARAKMT2ASMN1; SMN2
SCHEMBL5116066 0.72 CA2 (0.44) MEN1KMT2AHTTSMN1; SMN2
SCHEMBL629104 0.72 S1PR1 (0.43) PPARGPPARAKMT2A
SCHEMBL1775542 0.70 ALDH1A1 (0.52) ALDH1A1MEN1KMT2ASMN1; SMN2FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077854-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (BM) 2012-03-29 US disclosed
US-20120077854-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (BM) 2012-03-29 US disclosed
WO-2010120741-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (US) 2010-10-21 WO disclosed
WO-2010120741-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077854-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) RBP4, RBP1, FABP4 EIF4E 2920/4885AGPAT2 2624/4885JAK2 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.